

Research Article

A Simple Model for Assessment of Anti-Toxin Antibodies

Alex Skvortsov and Peter Gray

HPP Division, Defence Science and Technology Organisation, 506 Lorimer Street, Fishermans Bend, VIC 3207, Australia

Correspondence should be addressed to Alex Skvortsov; alex.skvortsov@dsto.defence.gov.au

Received 21 August 2012; Accepted 20 May 2013

Academic Editor: Nirmal K. Ganguly

Copyright © 2013 A. Skvortsov and P. Gray. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The toxins associated with infectious diseases are potential targets for inhibitors which have the potential for prophylactic or therapeutic use. Many antibodies have been generated for this purpose, and the objective of this study was to develop a simple mathematical model that may be used to evaluate the potential protective effect of antibodies. This model was used to evaluate the contributions of antibody affinity and concentration to reducing antibody-receptor complex formation and internalization. The model also enables prediction of the antibody kinetic constants and concentration required to provide a specified degree of protection. We hope that this model, once validated experimentally, will be a useful tool for in vitro selection of potentially protective antibodies for progression to in vivo evaluation.

1. Introduction

Passive immunization using antibodies has been used successfully for treatment and prophylaxis of infectious disease in humans, and there is increasing interest in the use of antibodies for treatment of infectious diseases that may be used as terrorist weapons, but for which the risk is not sufficiently high to justify preventive vaccination of a large civilian population (see [1–4] and references therein). Toxins are an important potential target for designing therapies against these threats and a broad range of approaches have been taken to develop inhibitors that may be of prophylactic or therapeutic use [1, 5].

Antibody engineering techniques allow affinity maturation of antibodies, and these techniques are being exploited to produce inhibitors for a number of toxins [6, 7]. The emphasis of this approach is on producing reagents with high affinity, based on the proposition that higher affinity will provide better protection.

However affinity, by itself, is a poor predictor of protective or therapeutic potential. Antibodies with high in vitro affinity for toxins do not automatically confer protection in vivo [8, 9] and may exacerbate the toxicity [10, 11]. The effects of using multiple antibodies with high affinities may be additive [12]

or synergistic [8] or without effect [9]. In addition, epitope specificity [13], antibody titre [14–18], and dissociation rate [19] have been correlated with protection.

Toxins are produced by a number of plants, animals and microorganisms. Toxins may act at the cell surface and either damage the cytoplasmic membrane or bind to a receptor and act via transmembrane signalling subsequent to that binding [20]. Alternatively, toxins may cross the cell membrane and act on intracellular targets [20]. For example, anthrax lethal toxin, ricin and cholera toxin bind to a cell surface receptor and make use of cellular membrane trafficking to enter the cell [21, 22].

The objective of this study is to develop a simple mathematical model that may be used to predict the optimum antibody parameters (kinetic constants and concentration) needed to inhibit the binding of the toxin to its receptor. These predictions may be used to select candidate antibodies for progression to in vivo evaluation and to assess the potential value of affinity enhancement.

This paper is an extension to our previous work [23]. In the model presented in the following we explicitly take into account the process of toxin internalization and diffusive fluxes around the cell.




FIGURE 1: Schematic representation of the model for receptor-toxin-antibody interaction.

2. Model

The kinetic model describing the interactions of toxins with cell receptors can be formulated based on the well-known analytical framework for ligand-receptor binding. The models of this process have been studied for many years and a vast amount of literature has accumulated on this subject (see [24–28] and references therein).

When a toxin diffuses in the extracellular environment and binds to the cell surface receptors, the toxin concentration will vary in both space and time. Any rigorous description of this process would entail a system of Partial Differential Equations (PDE), which couples extracellular diffusion with reaction kinetics of the cell surface. The resulting system of PDE is nonlinear and too complex to be treated analytically. This complexity makes any comprehensive study of parameter optimization unfeasible. From another perspective, it is well known that under some rather broad conditions (see [24–28] and references therein) the reaction-diffusion system of the ligand-receptor binding can be well approximated by a system of Ordinary Differential Equations in which the spatial variability of the process is simulated by different concentrations of species in initially predefined spatial domains (called compartments). Although this compartment model is significantly simpler than the initial reaction-diffusion system, it still allows a consistent description of reaction-diffusion transport in underlying system [25, 26, 28]. In the current paper we use the compartment-model approach for our analytical study and numerical simulations.

To begin, we consider the following simple model. The toxin, T , binds reversibly to cell surface receptors, R , with a forward rate k_1 and a reverse rate k_{-1} to form the toxin-receptor complex C_R which is then slowly internalized at a rate k_3 . The neutralizing antibody binds competitively to the toxin with on and off rates of k_2 and k_{-2} , respectively. The antibody-toxin complex, C_A , remains in the extracellular space (see Figure 1).

We can easily write an equation for the toxin-receptor binding (namely, without antibody being present). For

a spherical cell of radius a with the toxin binding to its surface [24–28],

$$\frac{dC_R}{dt} = k_f^e RT + k_r^e C_R, \quad (1)$$

where C_R is the concentration of the bound receptors (toxin-receptor complexes), R is the concentration of receptors, and T is the bulk toxin concentration (i.e., far from the cell surface) and is assumed to be spatially uniform. The effective forward and reverse rate coefficients are defined by [24–28]

$$k_f^e = \gamma k_1, \quad k_r^e = \gamma k_{-1}, \quad (2)$$

where k_1, k_{-1} are intrinsic reaction rates, $k_D = 4\pi aD$ is the diffusion rate, D is the diffusivity of toxin in the extracellular space, and $\gamma = 1/(1 + Rk_1/k_D) \leq 1$ [25–27].

The bulk concentration of toxin T is mainly driven by the binding to antibody. Therefore, in this case we can write an equation system similar to (1) but without any “diffusive” modification of the intrinsic rate constants:

$$\frac{dC_A}{dt} = k_2 AT + k_{-2} C_A, \quad (3)$$

where C_A is the concentration of toxin-antibody complexes and A is the concentration of antibody.

The process of toxin internalization is phenomenologically introduced into our model by the following equation:

$$\frac{dT_i}{dt} = k_3 C_R, \quad (4)$$

where T_i is the concentration of internalized toxin. The corresponding term should be included in (1), so we arrive at modified expression for k_r^e

$$k_r^e = \gamma k_{-1} - k_3. \quad (5)$$

The systems (1), (3), and (4) should be supplemented with three conservation laws for concentrations of R , T , and A :

$$R_0 = R + C_R, \quad (6)$$

$$A_0 = A + C_A, \quad (7)$$

$$T_0 = T + C_T + C_A + T_i, \quad (8)$$

where R_0, T_0 , and A_0 are the initial concentrations.

Equations (1), (3), (4), and (6)–(8) form a framework for our analysis. This is a system of nonlinear ODE (because of conservation laws (6)–(8) and because effective rates k_f^e, k_r^e are functions of the receptor concentration). It can be easily solved numerically and also allows some analytical progress (see the following). If parameter $\gamma \ll 1$ (and this is the case in many practical situations), then this model can be reduced to the “well-mixed” kinetic model with constant kinetic rates [23].

It is worth emphasizing that the aim of our analytical framework is to develop a simple but scientifically rigorous model that may be used to predict the optimum antibody kinetic properties and concentration required to achieve

TABLE 1: Kinetic constants used in numerical simulations (the binding of ricin to its receptor and the monoclonal antibody 2B11).

Reaction	Value
k_1	$1.3 \cdot 10^5 \text{ M}^{-1} \text{ s}^{-1}$
k_{-1}	$1.4 \cdot 10^{-2} \text{ s}^{-1}$
k_2	$1.25 \cdot 10^5 \text{ M}^{-1} \text{ s}^{-1}$
k_{-2}	$5.2 \cdot 10^{-4} \text{ s}^{-1}$
k_3	$3.3 \cdot 10^{-5} \text{ s}^{-1}$

a desired protective effect rather than develop a detailed, biologically accurate model that captures all the details of the toxin internalization process. Therefore, the model does not take into account the pharmacokinetics of the toxin-antibody complex [11] or receptor internalization and recycling [29, 30]. k_3 is a lumped constant that describes all the processes that result in the appearance of the free toxin in the intracellular space [31]. Wiley and Cunningham [32] and Shankaran et al. [33] have also developed mathematical models of this type of process.

We are particularly interested in the behaviour of the model under conditions most likely to reflect the real biological situation, that is, toxin concentration much lower than the concentration of receptors ($T_0/R_0 \ll 1$).

Testing of the model was carried out using COPASI (software application for simulation and analysis of biochemical networks and their dynamics [34]) and the kinetic parameters for the binding of ricin to its receptor and its internalization [35] and competition by the monoclonal antibody 2B11 [8]. The kinetic parameters used are shown in Table 1. The value of k_3 used is that determined by Sandvig et al. [35] to be the rate of irreversible binding of ricin to HeLa cells. For simplicity, the simulation was carried out using all reactions taking place in the same compartment.

To illustrate the model, we used toxin and receptor concentrations based on cell culture studies carried out in our laboratory. These typically use a cell concentration of $1 \cdot 10^4$ cells per $100 \mu\text{L}$ experiment and a ricin concentration of 10 pM . Assuming $3 \cdot 10^7$ receptors/cell [35], the receptor concentration is approximately 5 nM .

3. Analytical Results

3.1. Cell Surface Binding. Initially we derive some analytical results for toxins that act at the cell surface and are not internalized; that is, we set $k_3 = 0$ in (4). At equilibrium $d/dt = 0$ and from (1) and (3) we can write

$$C_R = \frac{RT}{K_1}, \quad C_A = \frac{AT}{K_2}, \quad (9)$$

where $K_1 = k_1/k_{-1}$, $K_2 = k_2/k_{-2}$ are the association constants for the toxin binding to the receptor and antibody, respectively. It is worth noting that the parameter γ (diffusive correction of the intrinsic reaction rates) disappears from (9), so in this case the analytical results are identical to ones derived using the ‘‘well-mixed’’ approximation [23].

In order to simplify notations, we denote by z and y the equilibrium concentrations of the toxin-receptor and toxin-antibody complexes; that is,

$$z = [C_R]_{\text{eq}}, \quad y = [C_A]_{\text{eq}}. \quad (10)$$

From (9) and conservation laws (6)–(8) the following closed equation for z can be derived:

$$(R_0 - z)(T_0 - z - y) - K_1 z = 0, \quad (11)$$

$$y = A_0 \frac{\epsilon z}{R_0 - z(1 - \epsilon)}, \quad (12)$$

where $\epsilon = K_1/K_2$.

Equation (11) can be written in a more conventional form of a cubic equation as follows:

$$a_3 z^3 + a_2 z^2 + a_1 z + a_0 = 0, \quad (13)$$

where

$$a_3 = \epsilon - 1,$$

$$a_2 = (1 - \epsilon)C_0 + \epsilon A_0 + R_0,$$

$$a_1 = -R_0(C_0 + A_0 + (1 - \epsilon)T_0), \quad (14)$$

$$a_0 = T_0 R_0^2,$$

and $C_0 = R_0 + K_1$.

It is well known that (13) has a closed-form analytical solution (Cardano’s formula [36]), which in our case provides a consistent way to derive exact solutions for the proposed model. Unfortunately these solutions still involve rather cumbersome expressions, which require further simplifications in order to be used in practical situations. In the following we present another approach that explicitly employs the smallness of ratio $T_0/R_0 \ll 1$ and leads to a simple analytical expression for the protective properties of the antibody.

We observe that in the absence of antibody (i.e., $A_0 = 0$), (11) is an elementary quadratic equation that has two roots. If we impose the obvious constraint $z \rightarrow 0$ as $T_0 \rightarrow 0$, then there is only one solution, which we designate as z_0 :

$$z_0 = \frac{C_0}{2} \left[1 - \left(1 - \frac{4R_0 T_0}{C_0^2} \right)^{1/2} \right]. \quad (15)$$

Under the condition $T_0/R_0 \ll 1$, this can be simplified to

$$z_0 \approx \frac{R_0 T_0}{C_0}, \quad C_0 = R_0 + K_1. \quad (16)$$

Let us now evaluate the effect of adding an antibody. From a mathematical point of view this effect (i.e., change of z under condition $A_0 > 0$) is captured entirely by the term y in (11), so our aim is to provide a reasonable analytical estimation of this term.

From (12) and based on our initial assumption of low toxin concentration ($T_0/R_0 \ll 1$), we can deduce the

following simple estimate $y \approx \epsilon z A_0 / R_0$. This then leads to a modified form of (11) as follows:

$$(R_0 - z)(T_0 - z) - K_* z = 0, \quad (17)$$

where

$$K_* = K_1 + \epsilon A_0. \quad (18)$$

We can see that this is the same form as the equation for z when $A_0 = 0$, but now with K_1 replaced with K_* . This also implies that the analytical solution (16) is still valid but only with the substitution $K_1 = K_*$.

In order to characterize the effect of an antibody on the binding of a toxin to its receptor, we introduce the nondimensional parameter Ψ , the relative reduction in C_R due to the introduction of an antibody as follows:

$$\Psi \equiv \frac{z(A_0 > 0)}{z(A_0 = 0)}. \quad (19)$$

The analytical results presented previously enable us easily to derive a simple formula for the antibody efficiency parameter Ψ . By using (10), (16), (18), and (19), we can readily deduce the following:

$$\Psi = \frac{1}{1 + \epsilon \lambda}, \quad \epsilon = \frac{K_1}{K_2}, \quad \lambda = \frac{A_0}{C_0}. \quad (20)$$

This expression is the main result of the current paper and will be validated with numerical simulations.

To conclude this section let us briefly discuss some additional constraints for the parameters of our model in order for the expression (20) to be valid. As mentioned above the condition of low toxin concentration is always assumed in our study. Another simple condition can be derived from the constraint $C_R + C_A \leq T_0$ and by using (16):

$$\frac{R_0}{C_0} \left(1 + \epsilon \frac{A_0}{C_0} \right) \approx \epsilon \frac{R_0 A_0}{C_0^2} \leq 1, \quad (21)$$

since $R_0/C_0 \leq 1$. This condition could always be checked retrospectively and always hold in our numerical simulations.

3.2. Toxin Internalization. For toxins that are internalized, the effect of antibodies that prevent receptor binding is to reduce the effective rate of internalization. To examine and evaluate this effect, we need to analyze the full systems (1), (3), and (4).

In order to characterize the effect of antibody concentration on the rate of toxin internalization, we introduce a new parameter as follows:

$$G = \frac{T_i(A_0 > 0)}{T_i(A_0 = 0)}, \quad (22)$$

which is a function of time (i.e., $G \equiv G(t)$).

Our aim is to deduce function G based on the kinetic models (1), (3), and (4). It is evident that $G \leq 1$ for $t > 0$ and $G \rightarrow 1$ as $t \rightarrow \infty$ (since in that case all toxin will be internalized).

For the toxins of interest, while the receptor binding is rapid (time scale $\sim 1/(k_1 C_0)$) [24, 26], the subsequent internalization is much slower (time scale $\sim 1/k_3 \gg 1/(k_1 C_0)$). This coupling of slow and fast processes in our system allows us to develop a simplified model of toxin internalization using the well-known framework of Quasi-Steady-State Approximation (QSSA); see [24–28, 37] and refs therein.

When applied to our system, QSSA elucidates the toxin internalization as a two-stage process. After the initial rapid binding of the toxin to the receptor we can simply set $dC_R/dt = 0$ in (1). The further slow evolution of $T(t)$ (namely, quasi-steady state) is completely determined by the conservation laws (8) and (4) and spans a time scale of the order of the internalization time ($\sim 1/k_3$). In addition, for solving (4) at the initial stage of internalization, we can assume that $T_i \ll T_0$ and write

$$T_i(t) = k_3 z_0 t, \quad t \ll \frac{1}{k_3}, \quad (23)$$

where z_0 is given by expressions (15) and (16). The evolution of $T_i(t)$ for the late stage of internalization can be readily derived from (4) and (6)–(8) by assuming $[T_0 - T_i(t)] \ll T_0$:

$$T_i(t) = T_0 [1 - \exp(-k_3 t)], \quad t \geq \frac{1}{k_3}, \quad (24)$$

so $T_i(t)$ exponentially approaches its saturation limit. A simulation of this process is shown in Figure 5, and the slow linear increase of T_i at the initial stage is clearly visible.

Now, consider the case where $A_0 > 0$. According to (23) the main effect of the introduction of an antibody is to reduce the value of z_0 , as described in the previous section. Then, based on (22), (23), and (19) we can conclude that, during the quasi-equilibrium stage, the following approximation holds:

$$G = \frac{T_i(A_0 > 0)}{T_i(A_0 = 0)} \approx \Psi, \quad (25)$$

where Ψ is given by expression (20).

The overall effect of introducing an antibody can be best described in terms of the internalization half-time, τ_i . Without antibody the latter can be estimated from (24) and condition $T_i(\tau_i) = T_0/2$. Thus from (23) we yield

$$\tau_i \approx \frac{T_0}{2k_3 z_0} = \frac{C_0}{2k_3 R_0}. \quad (26)$$

For the internalization time with the presence of antibody we can apply reduced value of z_0 and write the following simple formula:

$$\frac{\tau_i}{\tau_i^0} \approx \frac{1}{\Psi}, \quad (27)$$

where τ_i^0 is the internalization time in the absence of antibody ($A_0 = 0$).

Equations (26) and (27) have a clear interpretation. As described in the previous section, the introduction of an antibody results in a decrease, at $t \ll \tau_i$, in the equilibrium

value of C_R (i.e., in z_0). This can be related, in accordance with (23) and (26), to a corresponding decrease in the concentration of internalized toxin T_i and a consequent increase in the toxin internalization time (since it takes longer to achieve a give level of T_i). Since changes in z_0 can be described comprehensively by means of the parameter Ψ , it still remains the only parameter needed to characterize the influence of an antibody on the concentration of internalized toxin (25), (27).

It is evident that the two main effects described above (reduction of the concentration of internalized toxin at a given time and increase in the time required for the internalized toxin to reach a given concentration) are not independent of each other. The linear relationships (25), (27) allow us to establish a general identity that relates these two effects for any time t .

Let us assume that for $A_0 = 0$, τ_0 is the time taken for the internalized toxin to reach a concentration T_i^0 (i.e., $\tau^0 = T_i^0 / (k_3 z_0)$; see (23)). The effect of introducing an antibody is to reduce the internalized toxin concentration to a value $T_i \leq T_i^0$. Then from (25), (27) we can derive the following identity:

$$T_i \tau_i = T_i^0 \tau_i^0, \tag{28}$$

where τ_i is the time required for the internalized toxin to reach T_i^0 when $A_0 > 0$. The identity (28) has no explicit dependency on antibody kinetic parameters or concentration and provides an easy way to calculate any of the parameters ($T_i, T_i^0, \tau_i, \tau_i^0$) if the other three are known.

4. Numerical Results and Discussion

We have derived an analytical expression for the parameter Ψ , the relative ability of an antibody to reduce the binding of a toxin to its receptor (20). Our derivation is based on the following assumptions:

- (1) toxin concentration is much lower than the receptor concentration,
- (2) for toxins that are internalized, the internalization rate is much slower than establishment of the receptor-toxin binding equilibrium.

Applying these assumptions, we found that parameter Ψ is independent of the toxin concentration (see (20)); that is, it is determined by the ratio of antibody to receptor concentration and not by the ratio of antibody to toxin concentration as commonly used. For the low toxin/receptor ratios likely to occur in biological situations, the condition (21) can be met by large range of antibody kinetic parameters. From this point of view (20) should be valid for most practical applications.

The implications of our analytical findings are illustrated by simulation of the complete kinetic models ((1),(3), (4), and (6)–(8)) using the kinetic constants for ricin and the anti-ricin antibody 2B11 (Table 1). Figure 2 is a simulation of the effect of the presence of an antibody on the binding of the toxin to its receptor (formation of C_R). The antibody concentration is expressed as the dimensionless parameter $\lambda = A_0/C_0$. In this




FIGURE 2: Simulated effect of antibody concentration on formation of toxin-receptor complexes C_R . Parameter $\lambda = A_0/C_0$, $C_0 = R_0 + K_1$. The binding curves were created using the simulation package COPASI and the kinetic constants in Table 1. $R_0 = 5 \text{ nM}$, $T_0 = 10 \text{ pM}$, $C_0 = 1.15 \cdot 10^{-7}$.




FIGURE 3: Effect of antibody concentration on protection factor. Parameter Ψ (19) was determined from (20) (solid lines) and by using simulated values of C_R from Figure 2 at 2500 sec (Δ), $\epsilon = 25.9$.

case, since R_0 and $T_0 \ll K_1$, the parameter $C_0 = R_0 + K_1$ is dominated by K_1 ($1.08 \cdot 10^{-7}$).

Figure 3 shows the effect of increasing antibody concentration on Ψ . There is a good agreement between the values of Ψ determined from (20) and from (19) using the equilibrium values of C_R determined from simulation of the complete kinetic model (Figure 3). For instance, the results predict that, for this toxin and antibody combination, the additional protection provided by increasing the antibody concentration diminishes rapidly when λ exceeds 0.1.

Figure 4 shows the relationship (20) between Ψ , antibody concentration and the toxin/antibody and the ratio of toxin/receptor dissociation constants (ϵ). This plot is valid for all combinations of toxin, receptor, and antibody consistent with the assumptions used to derive (20), principally




FIGURE 4: Protection factor Ψ (19) as a function of parameter $\epsilon = K_1/K_2$ and $\lambda = A_0/C_0$ ((20)): $\lambda = 0.01$ (\circ); 0.025 (Δ); 0.05 (\square); 0.1 (∇); 0.25 (\diamond). The range of values for λ and ϵ below dashed line corresponds to 80% protection.




FIGURE 5: Different time scales for formation of receptor-toxin complex C_R (\square) and associated toxin internalization T_i (solid lines). Results of COPASI simulation with kinetic constants from Table 1. $\lambda = A_0/C_0$, $R_0 = 5$ nM, $T_0 = 10$ pM, $C_0 = 1.15 \cdot 10^{-7}$, $\epsilon = 25.9$.

$T_0 \ll R_0$. The antibody kinetic parameters and concentration required to provide a specified degree of protection may be determined from this plot. For example, any combination of ϵ and λ falling below the dashed line will reduce either C_R or T_i by 80%.

This, in turn, enables important judgements to be made about antibody selection. For example, if an antibody concentration of $0.25C_0$ ($\lambda = 0.25$) is achievable, then an antibody with an ϵ value of 50 will provide good protection (93% reduction in C_R or T_i). If an antibody concentration of only $0.05C_0$ ($\lambda = 0.05$) is achievable, then an ϵ value of 250 is required to achieve the same level of protection. The structure of (20) is such that a given increase in protection (Ψ or Γ) may be achieved by either an x -fold increase in ϵ or an x -fold increase in λ .




FIGURE 6: Comparison of parameters Ψ and Γ . Γ (Δ) was determined using values of T_i and T_i^0 at $t = 10^4$ sec from toxin internalization time courses simulated using COPASI and the kinetic constants in Table 1. Parameter Ψ (solid line) was determined from (20). $R_0 = 5$ nM, $T_0 = 10$ pM, $C_0 = 1.15 \cdot 10^{-7}$, $\epsilon = 25.9$.




FIGURE 7: Establishment of the quasi-equilibrium state in the presence of antibody. C_R formation (Δ) was simulated using COPASI and the kinetic constants in Table 1. Γ (\square) was determined using (25) and values T_i and T_i^0 at $t = 10^4$ sec using simulated toxin internalization time courses. $R_0 = 5$ nM, $T_0 = 10$ pM, $C_0 = 1.15 \cdot 10^{-7}$, $\lambda = 0.05$.

The effect of antibody on toxin internalization is simulated in Figure 5. Rapid equilibration of receptor and toxin is followed by slow accumulation of toxin within the cell. Equation (25) predicts that Ψ is the only parameter needed to characterize the influence of an antibody on toxin internalization. Figure 6 compares Γ calculated using (25), (20) with Γ determined using values of T_i and T_i^0 at $t = 10^4$ sec from this simulated data and shows good agreement between the two values under the condition $T_0 \ll R_0$, although the value of Γ is slightly greater than Ψ . The plot predicts the degree of protection provided by a given concentration of antibody and enables assessment of the value of increasing antibody concentration beyond a certain value. For example,




FIGURE 8: Relationship between toxin internalization time τ_i and protection factor Ψ (19). Solid line is formula (27) and (\square) is simulation with COPASI. τ_i was determined as the time to internalize $5 \cdot 10^{-14}$ M of ricin. All other parameters are the same as in Figure 7.

to enhance the reduction of T_i from 90% to 95% requires doubling of A_0 .

The expression for Ψ , (20), assumes a quasi-equilibrium state in the system. In practice, this state may take significant time to be achieved. Figure 7 shows a simulation of the time taken by the ricin/receptor/2B11 system to reach the quasi-equilibrium state for $\lambda = 0.05$. The value of Γ determined from the toxin internalization profiles (Figure 7) parallels this process; that is, experimental validation of Γ must allow sufficient time to elapse for the quasi-equilibrium state to be established.

The relationship between the internalization time τ_i and Ψ described in (27) is shown in Figure 8. Ψ was determined from simulated toxin internalization time courses (Figure 5) as the time to internalize $5 \cdot 10^{-14}$ M ricin. The slope of the fitted line is 1.07, close to the predicted value of 1.0.

In summary, the protection provided by an antibody against toxins that act either at the cell surface or after binding to the cell surface followed by internalization may be predicted from a simple kinetic model. Protection parameter Ψ is a simple function of antibody, receptor, and toxin concentrations and the kinetic parameters governing the binding of the toxin to the receptor and antibody:

$$\Psi = \frac{1}{1 + (K_1/K_2)(A_0/C_0)}. \quad (29)$$

The calculated value of Ψ matches closely the degree of protection determined from numerical simulation of the binding and internalization reactions and provides a convenient method for predicting the optimum antibody parameters (concentration and dissociation constants) needed to provide effective treatment or prophylaxis for toxins.

Acknowledgments

The authors acknowledge helpful discussions with Dr. Chris Woodruff and Dr. Ralph Leslie.

References

- [1] R. B. Reisler and L. A. Smith, "The need for continued development of ricin countermeasures," *Advances in Preventive Medicine*, vol. 2012, Article ID 149737, 4 pages, 2012.
- [2] J. Prigent, L. Panigai, P. Lamourette et al., "Neutralising antibodies against ricin toxin," *PLoS ONE*, vol. 6, no. 5, Article ID e20166, 2011.
- [3] H. B. Oral, C. Ozakin, and C. A. Akdis, "Back to the future: antibody-based strategies for the treatment of infectious diseases," *Molecular Biotechnology*, vol. 21, pp. 225–239, 2002.
- [4] A. F. Kaufmann, M. I. Meltzer, and G. P. Schmid, "The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable?" *Emerging Infectious Diseases*, vol. 3, no. 2, pp. 83–94, 1997.
- [5] G. J. A. Rainey and J. A. T. Young, "Antitoxins: novel strategies to target agents of bioterrorism," *Nature Reviews Microbiology*, vol. 2, no. 9, pp. 721–726, 2004.
- [6] M. Nehal, C. Michelle, L. Juan et al., "A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized," *Infection and Immunity*, vol. 73, pp. 795–802, 2005.
- [7] A. Razai, C. Garcia-Rodriguez, J. Lou et al., "Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin type A," *Journal of Molecular Biology*, vol. 351, no. 1, pp. 158–169, 2005.
- [8] C. R. McGuinness and N. J. Mantis, "Characterization of a novel high-affinity monoclonal immunoglobulin G antibody against the ricin B subunit," *Infection and Immunity*, vol. 74, no. 6, pp. 3463–3470, 2006.
- [9] H. F. Staats, S. M. Alam, R. M. Scearce et al., "In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity," *Infection and Immunity*, vol. 75, no. 11, pp. 5443–5452, 2007.
- [10] M. Maddaloni, C. Cooke, R. Wilkinson, A. V. Stout, L. Eng, and S. H. Pincus, "Immunological characteristics associated with the protective efficacy of antibodies to ricin," *Journal of Immunology*, vol. 172, no. 10, pp. 6221–6228, 2004.
- [11] E. D. Lobo, R. J. Hansen, and J. P. Balthasar, "Antibody pharmacokinetics and pharmacodynamics," *Journal of Pharmaceutical Sciences*, vol. 93, no. 11, pp. 2645–2668, 2004.
- [12] M. T. Albrecht, H. Li, E. D. Williamson et al., "Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against *Bacillus anthracis* infection and enhance endogenous immunity to anthrax," *Infection and Immunity*, vol. 75, no. 11, pp. 5425–5433, 2007.
- [13] T. J. Smith, J. Lou, I. N. Geren et al., "Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization," *Infection and Immunity*, vol. 73, no. 9, pp. 5450–5457, 2005.
- [14] S. Reuveny, M. D. White, Y. Y. Adar et al., "Search for correlates of protective immunity conferred by anthrax vaccine," *Infection and Immunity*, vol. 69, no. 5, pp. 2888–2893, 2001.
- [15] S. F. Little, B. E. Ivins, P. F. Fellows, M. L. M. Pitt, S. L. W. Norris, and G. P. Andrews, "Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine," *Vaccine*, vol. 22, no. 3–4, pp. 422–430, 2004.
- [16] M. L. M. Pitt, S. F. Little, B. E. Ivins et al., "In vitro correlate of immunity in a rabbit model of inhalational anthrax," *Vaccine*, vol. 19, no. 32, pp. 4768–4773, 2001.

- [17] K. K. Peachman, M. Rao, C. R. Alving et al., "Correlation between lethal toxin-neutralizing antibody titers and protection from intranasal challenge with *Bacillus anthracis* ames strain spores in mice after transcutaneous immunization with recombinant anthrax protective antigen," *Infection and Immunity*, vol. 74, no. 1, pp. 794–797, 2006.
- [18] N. Mohamed, M. Clagett, J. Li et al., "A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized *Bacillus anthracis* spore challenge," *Infection and Immunity*, vol. 73, no. 2, pp. 795–802, 2005.
- [19] G. A. Papalia, M. Baer, K. Luehrsen, H. Nordin, P. Flynn, and D. G. Myszka, "High-resolution characterization of antibody fragment/antigen interactions using Biacore T100," *Analytical Biochemistry*, vol. 359, no. 1, pp. 112–119, 2006.
- [20] J. E. Alouf and M. R. Popoff, *The Comprehensive Sourcebook of Bacterial Protein Toxins*, Elsevier, Amsterdam, The Netherlands, 3rd edition, 2006.
- [21] K. Sandvig and B. van Deurs, "Membrane traffic exploited by protein toxins," *Annual Review of Cell and Developmental Biology*, vol. 18, pp. 1–24, 2002.
- [22] K. Sandvig and B. van Deurs, "Transport of protein toxins into cells: pathways used by ricin, cholera toxin and Shiga toxin," *FEBS Letters*, vol. 529, no. 1, pp. 49–53, 2002.
- [23] A. Skvortsov and P. Gray, "Modeling and simulation of receptor-toxin-antibody interaction," in *Proceedings of the 18th World IMACS Congress and International Congress on Modelling and Simulation (MODSIM '09)*, pp. 185–191, Cairns, Australia, July 2009.
- [24] G. A. Truskey and F. Yuan, *Transport Phenomena in Biological Systems*, Prentice Hall, New York, NY, USA, 2nd edition, 2009.
- [25] D. A. Lauffenburger, *Receptors: Models for Binding, Trafficking, and Signaling*, Oxford University Press, Oxford, UK, 2nd edition, 1993.
- [26] B. Goldstein and M. Dembo, "Approximating the effects of diffusion on reversible reactions at the cell surface: ligand-receptor kinetics," *Biophysical Journal*, vol. 68, no. 4, pp. 1222–1230, 1995.
- [27] M. Coppey, A. M. Berezhkovskii, S. C. Sealson, and S. Y. Shvartsman, "Time and length scales of autocrine signals in three dimensions," *Biophysical Journal*, vol. 93, no. 6, pp. 1917–1922, 2007.
- [28] S. Ghosh, M. Gopalakrishnan, and K. Forsten-Williams, "Self-consistent theory of reversible ligand binding to a spherical cell," *Physical Biology*, vol. 4, no. 4, pp. 344–352, 2007.
- [29] F. R. Maxfield and T. E. McGraw, "Endocytic recycling," *Nature Reviews Molecular Cell Biology*, vol. 5, no. 2, pp. 121–132, 2004.
- [30] D. R. Sheff, E. A. Daro, M. Hull, and I. Mellman, "The receptors recycling pathway contains two distinct populations of early endosomes with different sorting functions," *Journal of Cell Biology*, vol. 145, no. 1, pp. 123–139, 1999.
- [31] C. Lamaze and L. Johannes, "Intracellular trafficking of bacterial and plant protein toxins," in *The Comprehensive Sourcebook of Bacterial Protein Toxins*, J. E. Alouf and N. R. Popoff, Eds., pp. 135–153, Elsevier, Amsterdam, The Netherlands, 3rd edition, 2006.
- [32] H. S. Wiley and D. D. Cunningham, "A steady state model for analyzing the cellular binding, internalization and degradation of polypeptide ligands," *Cell*, vol. 25, no. 2, pp. 433–440, 1981.
- [33] H. Shankaran, H. Resat, and H. S. Wiley, "Cell surface receptors for signal transduction and ligand transport: a design principles study," *PLoS Computational Biology*, vol. 3, no. 6, article e101, 2007.
- [34] S. Hoops, R. Gauges, C. Lee et al., "COPASI—a complex pathway simulator," *Bioinformatics*, vol. 22, no. 24, pp. 3067–3074, 2006.
- [35] K. Sandvig, S. Olsnes, and A. Pihl, "Kinetics of binding of the toxic lectins abrin and ricin to surface receptors of human cells," *The Journal of Biological Chemistry*, vol. 251, no. 13, pp. 3977–3984, 1976.
- [36] A. D. Polyaniin and A. V. Manzhirov, *Handbook of Mathematics for Engineers and Scientists*, CRC Press, New York, NY, USA, 2007.
- [37] A. R. Tzafiriri and E. R. Edelman, "On the validity of the quasi-steady state approximation of bimolecular reactions in solution," *Journal of Theoretical Biology*, vol. 233, no. 3, pp. 343–350, 2005.